Market Access Multiple myeloma drug Blenrep backed for wider NHS use PharmaphorumThe revitalisation of GSK's Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely.Market AccessOncologyRead full story pharminent April 17, 2026 (Last updated: April 17, 2026) Pharmaphorum The revitalisation of GSK’s Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely. Market AccessOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Daiichi Sankyo and Interna partner for MNM-targeted delivery solutionsNext: Replimune cries foul on regulatory flexibility. But many Americans want a stricter FDA Related Stories Market Access pharminent June 12, 2026 Market Access Aquipta recommended by NICE for acute migraine treatment pharminent June 10, 2026 Market Access AbbVie’s migraine drug cleared for migraine attacks on NHS pharminent June 10, 2026
